Cytokinetics will provide an update on the company’s cardiac myosin inhibitor programs and plans to build a specialty cardiology franchise at its virtual Investor and Analyst Day, “New Horizons in Hypercontractility” (34.30)
- New long-term data from FOREST-HCM, the open-label extension study of aficamten, show sustained improvements in clinical efficacy endpoints and no treatment interruptions for low ejection fraction.
- Commercial readiness activities leverage insights from market research to inform market segmentation and patient-centric strategies.
- New pre-clinical data for CK-586 shows improved diastolic function and reduced cardiac fibrosis in animal model of HFpEF; Phase 1 study ongoing.